Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation
Report of the Guideline Development Subcommittee of the American Academy of Neurology
Citation Manager Formats

Article Information
- Received May 21, 2013
- Accepted in final form October 15, 2013
- First Published February 24, 2014.
Author Information
- Antonio Culebras, MD, FAAN, FAHA,
- Steven R. Messé, MD, FAAN, FAHA,
- Seemant Chaturvedi, MD, FAAN, FAHA,
- Carlos S. Kase, MD, FAAN, FAHA and
- Gary Gronseth, MD, FAAN
- Antonio Culebras, MD, FAAN, FAHA,
NONE
NONE
J Uriach & Co. S.A. Travel fund to make presentation at European Stroke Congress, Lisbon, May 2012.
(1) Medlink, Associate Editor; (2) Medreviews, Associate Editor (discontinued).
NONE
(1)Case studies in sleep neurology, 2012, Cambridge University Press, UK. (2) Sleep apnea, stroke and cardiovascular disease, 2013, Cambridge University Press, UK. (UK)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Clinical Stroke Research, Inc., NY.
NONE
NONE
NONE
NONE
NONE
- Steven R. Messé, MD, FAAN, FAHA,
(1) DSMB for an NIH/NINDS study of tPA in pediatric stroke
NONE
NONE
NONE
NONE
Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults, Antiplatelet therapy for secondary prevention of stroke, Up To Date, Inc. 2006 - present
NONE
Glaxo Smith Kline
NONE
NONE
NONE
WL Gore, local PI, 2009 - present Glaxo Smith Kline, National co-PI, 2013-present
1) NIH/NIDDK, U01-DK060990, endpoint adjudication committee, 2007 - present. 2) NIH/NINDS, U01 NS40406-04, local PI, 2008 - 2013. 3) NIH/NHLBI, 1R01HL084375-01A2, subinvestigator in charge of neurologic assessments, 2009-2012, 4) NIH/NHLBI, HHSN268200800003C, back-up medical monitor, 2010-2013, 5) NIH/NHLBI UM1 HL088957-06, subinvestigator 2013 - present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Seemant Chaturvedi, MD, FAAN, FAHA,
Executive Committee member for ACT I study
NONE
NONE
Editorial board member of NEUROLOGY and STROKE and contributing editor for NEJM Journal Watch Neurology
NONE
NONE
NONE
Consulting honoraria for Genentech, Boehringer-Ingelheim, Abbott Vascular, Thornhill research, Bristol Myers Squibb, WL Gore
NONE
NONE
NONE
Clinical studies supported by Daiichi, Astra Zeneca
NINDS for serving on grant review committee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Compensation for expert witness testimony
- Carlos S. Kase, MD, FAAN, FAHA and
Lundbeck A/S; investigator, Desmoteplase in Acute Ischemic Stroke Trial (DIAS4): A randomized, double-blind, parallel-group placebo controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke.
NONE
NONE
Journal of Stroke and Cerebrovascular Diseases, Editorial Board member, 5 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH/NHLBI, Contract N01-HC-25195 (PI: Wolf; The Framingham Heart Study, Physical Examination, Testing, and Surveillance). Role: Co-Investigator. 10/01/08- 03/31/15. (2) NIH/NINDS, 2 R01-NS17950-27 (PI: Wolf; Precursors of Stroke Incidence and Prognosis). Role: Co-Investigator. 12/01/81-06/30/14. (3) NINDS, 2U01NS38529-04A1 (PI: Benavente; Secondary Prevention of Small Subcortical Strokes [SPS3]). Role: Co-Investigator. 06/01/03-01/31/12. (4) NINDS, 1 R01 NS 44876 01A2 (PI: Kernan; Insulin Resistance Intervention after Stroke Trial [IRIS]). Role: Co-Investigator. 09/01/04-08/31/11. (5) NINDS, 1580G HJ344 (PI: Kidwell; MR and Recanalization of Stroke Clots Using Embolectomy [MRRESCUE]). Role: Co-Investigator. 04/01/08-04/01/10
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gary Gronseth, MD, FAAN
NONE
NONE
NONE
(1) Neurology Now, Editorial advisory board, Inception-Present (2) Neurology, Associate Editor, 2013-Present
NONE
NONE
NONE
NONE
Boehringer Ingelheim 2007-2011(Resigned Dec 2011)
NONE
NONE
NONE
NONE
NONE
American Academy of Neurology
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (A.C.), SUNY Upstate Medical University, Syracuse, NY; the Department of Stroke and Neurocritical Care (S.R.M.), Hospital of the University of Pennsylvania and the Pennsylvania Hospital, Philadelphia; the Stroke Program (S.C.), Wayne State University School of Medicine, Detroit, MI; the Department of Neurology (C.S.K.), Boston University School of Medicine and Boston Medical Center, Boston, MA; and the Department of Neurology (G.G.), University of Kansas Medical Center, Kansas City, KS.
- Correspondence to American Academy of Neurology: guidelines{at}aan.com
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Author response to correspondence from Dr. Lopez ValleGary GronsethPublished November 03, 2016
- Reply to Perez-Gomez et al.Antonio CulebrasPublished April 02, 2014
- Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of NeurologyFrancisco Perez-GomezPublished April 01, 2014
- Author Response to Hart, Eikelboom NCP Guideline CommentaryAntonio CulebrasPublished March 24, 2014
- Regarding a p-valueRaul G. Lopez VallePublished March 24, 2014
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.